Long-term therapy of idiopathic inflammatory bowel disease
Authors:
K. Lukáš 1; M. Dastych 2; A. Novotný 1; L. Prokopová 2; V. Zbořil 2
Authors‘ workplace:
Univerzita Karlova v Praze, 1. lékařská fakulta, IV. interní klinika VFN
1; Masarykova univerzita v Brně, Lékařská fakulta, Interní gastroenterologická klinika FN
2
Published in:
Čas. Lék. čes. 2012; 151: 231-242
Category:
Review Articles
Overview
Crohn’s disease and ulcerative colitis are chronic inflammatory diseases of the gastrointestinal tract. Both can be treated with medications that induce and maintain remission. The choice of medication is influenced by the balance between drug potency and potential side-effects, previous response to treatment, and the presence of extraintestinal manifestations or complications. After remission has been achieved, the goal of treatment is to maintain the symptom-free status. 5-aminosalicylic acid derivatives have efficacy for maintenance of remission in patients with distal disease. Thiopurines are recommended for the long-term therapy. For the patients who do not have a response to immunosuppressive therapy or cannot tolerate it, anti-TNF-α agents are gradually being adopted. Effective in the remission maintenance are thiopurines, infliximab and adalimumab.
Key word:
Crohn’s disease, ulcerative colitis, remission, long-term therapy, aminosalicylates, antibiotics, glucocorticosteroids, thiopurines, infliximab, adalimumab.
Sources
1. Pithadia AB, Jain S. Treatment of inflammatory bowel disease. Pharmacol Rep 2011; 63(3): 629–642.
2. Lichtenstein GR, Hanauer SB, Sandborn WJ, The Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn’s disease in adults. Am J Gastroenterol 2009; 104: 465–483.
3. Arai R. Therapy Adherence in Crohn’s Disease: An Adult Case Study. Case Rep Gastroenterol 2010; 4: 153–157.
4. Peyrin-Biroulet L, Lémann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease.Aliment Pharmacol Ther 2011; 33(8): 870–879.
5. Prantera C, Scribano ML. Which type of treatment is advisable in the prevention of recurrence after surgery in Crohn’s disease? Inflamm Bowel Dis 2008; 14(Suppl 2): S277–278.
6. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gu. 2001; 49(6): 777–782.
7. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis 2002; 8(4): 244–250.
8. Michener WM, Whelan G, Greenstreet RL, Farmer RG. Comparison of the clinical features of Crohn’s disease and ulcerative colitis with onset in childhood or adolescence. Cleve Clin Q 1982 Spring; 49(1): 13–16.
9. Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007; 132(2): 507–515.
10. Loftus EV Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002; 16(1): 51–60.
11. Etienney I, Bouhnik Y, Gendre JP, et al. Crohn’s disease over 20 years after diagnosis in a referral population. Gastroenterol Clin Biol 2004; 28(12): 1233–1239.
12. Stenson WF, Hanauer SB, Cohen RS. Inflammatory bowel disease. In: Yamada T, ed. Textbook of gastroenterology. Willey-Blackwell Oxford 2009; 1386–1472.
13. Mowat C, Cole A, Windsor A. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60(5): 571–607.
14. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121(2): 255–260.
15. Edwards EC, Truelove SC. The course and prognosis of ulcerative colitis. Gut 1963; 4: 299–315.
16. Rutgeerts P. Review article: recurrence of Crohn’s disease after surgery – the need for treatment of new lesions. Aliment Pharmacol Ther 2006; 24(Suppl 3): 29–32.
17. Nos P, DomŹnech E. Postoperative Crohn’s disease recurrence: A practical approach. World J Gastroenterol 2008; 14(36): 5540–5548.
18. Sankey EA, Dhillon AP, Anthony A, et al. Early mucosal changes in Crohn’s disease. Gut 1993; 34: 375–381.
19. Yamamoto T. Factors affecting recurrence after surgery for Crohn’s disease. World J Gastroenterol 2005; 11: 3971–3979.
20. Lukáš K. Idiopatické střevní záněty – predikce průběhu a včasná léčba. Čas Lék čes 2011; 150(6): 315–320.
21. Loly C, Belaiche J, Louis E. Predictors of severe Crohn’s disease. cand J Gastroenterol 2008; 43: 948–954.
22. Abraham C, Cho JH. Inflammatory Bowel disease. N Engl J Med 2009; 361(21): 2066–2078.
23. Danese S, Fiocchi C. Ulcerative Colitis. N Engl J Med 2011; 365(18): 1713–1725.
24. D’Haens G, aert , an Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008; 371(9613): 660–667.
25. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000; 119: 895–902.
26. Cosnes J, Seksik P. Inflammatory bowel disease: from sulfasalazine to biologics. Gastroenterol Clin Biol 2009; 33(8–9): 692–701.
27. Hanauer SB. Clinical perspectives in Crohn’s disease. Turning traditional treatment strategies on their heads: current evidence for „step-up“ versus „top-down“. Rev Gastroenterol Disord 2007; 7(Suppl 2): S17–22.
28. Bodger K. Cost effectiveness of treatments for inflammatory bowel disease. Pharmacoeconomics 2011; 29(5): 387–401.
29. Shergill AK, Terdiman JP. Controversies in the treatment of Crohn’s disease: the case for an accelerated step-up treatment approach. World J Gastroenterol 2008; 14(17): 2670–2677.
30. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 2010; 138(2): 463–468.
31. Su C, Lichtenstein GR. Ulcerative Colitis. In: Feldman M, Friedman LS, Brandt LJ. (eds.) Sleisenger and Fordtrans Gastrointestinal and Liver Disease. 8th edition. Saunders Elservier Philadelphia 2006; 2499–2548.
32. Pariente B, Cosnes J, Danese S, et al. Development of the Crohn’s Digestive Damage Score, the Léman Score. Inflamm Bowel Dis 2011; 17(6): 1415–1422.
33. Yanai H, Hanauer SB. Assessing Response and Loss of Response Biological Therapies in IBD. Am J Gastroenterolol 2011; 106: 685–698.
34. Dignass A, Van Assche G., Lindsay JO, Lémann M, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease. JCC 2010; 4: 40–50.
35. Hamlin PJ, Warren L, Everett SM. Establishing a biologics service for patients with inflammatory bowel disease. Frontline Gastroenterology 2011; 2: 133–139.
36. D’Albasio G, Trarolli G, Ghetti A, et al. Intermittent therapy with high-dose 5-aminosalicylic enemas for maintenance remission in ulcerative proctosigmoiditis. Dis Colon Rectum 1990; 33: 394–397.
37. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; 2: CD000544.
38. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14(3): 354–377.
39. Hecht TE, Su CG, Lichtenstein GR. Medical therapy of inflammatory bowel disease. In: Cohen RD. (ed.) Inflammatory bowel disease: diagnosis and therapeutics. Totowa, New Yersey: Humana Press 2003: 131–156.
40. Travis SP, Stange EF, Leman M, et al. European evidence – based consensus on the management of ulcerative colitis: Current management. J Crohn Colitis 2008; 2: 24–62.
41. Bernstein CN, Krabshuis JH, Fedail S, t al. World gastroenterology organization practice guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Disease 2010; 16(1): 112–124.
42. d’Albasio G, Pacini F, Camarri F, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997; 92: 1143–1147.
43. Ford AC, Khan KJ, Achkar J-P, Moayyedi P. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; doi: 10.1038/ajg.2011.410
44. Travis SP, Stange EF, Lémann M, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006; 55(Suppl 1): i16–35.
45. Sands BE. Crohn’s Disease. In: Feldman M, Friedman LS, Brandt LJ. (eds.) Sleisenger and fordtrans gastrointestinal and liver disease. 8th edition. Philadelphia: Saunders Elservier 2006; 2459–2498.
46. Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn’s disease. A meta-analysis adjusted for confounding variables. Gastroenterology 1997; 113: 1465–1473.
47. Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn’s disease: a multicenter placebo-controlled study. The Groupe d‘Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Gastroenterology 1993; 104(2): 435–439.
48. Esser D, Cornillie F, Diamond RH, Spiegel RJ. On the updated ECCO consensus guidelines for medical management of Crohn’s disease. J Crohns Colitis 2011; 5(2): 165–166.
49. Stange EF, Travis SP, Vermeire S, et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008; 2(1): 1–23.
50. Rutgeerts P, Hiele M, Geboes K, t al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 1995; 108: 1617–1621.
51. Yamamoto T, Nakahigashi M, Umegae S, Matsumoto K. Enteral nutrition for the maintenance of remission in Crohn’s disease: a systematic review. Eur J Gastroenterol Hepatol 2010; 22(1): 1–8.
52. Yamamoto T, Nakahigashi M, Umegae S, Matsumoto K. Prospective clinical trial: enteral nutrition during maintenance infliximab in Crohn’s disease. J Gastroenterol. 2010; 45(1): 24–29.
53. Yamamoto T, Nakahigashi M, Saniabadi AR, Iwata T, Maruyama Y, Umegae S, Matsumoto K. Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn’s disease: a prospective study. Inflamm Bowel Dis 2007; 13(12): 1493–1501.
54. Lochs H. Enteral nutrition-the new maintenance therapy in Crohn’s disease? Inflamm Bowel Dis 2007; 13(12): 1581–1582.
55. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15(6): 697–698.
56. Kruis W, Frič P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53(11): 1617–1623.
57. Do VT, Baird BG, Kockler DR. Probiotics for maintaining remission of ulcerative colitis in adults. Ann Pharmacother 2010; 44(3): 565–571.
58. Thomas S, Metzke D, Schmitz J, Dörffel Y, Baumgart DC. Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn’s disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol 2011; 301(5): 1083–1092.
59. Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev 2000; 2: CD000301.
60. Van Asche G, Dignass A, Panes J, et al. The second European evidence-based consensus on diagnosis and management of Crohn’s disease: Definition and diagnosis. J Crohn’s Colitis 2010; 4(1): 7–27.
61. van Asche G, Dignass A, Reinisch W, et al. The second European evidence-based consensus on diagnosis and management of Crohn’s disease: Special situations. J Crohn’s Colitis 2010; 4(1): 63–101.
62. Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situation. Gut 2006; 55(Suppl 1): i36–58.
63. Ardizzone S, Maconi G, Russo A, Ibesi V, Colombo E, Bianchi Porro C. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55: 47–53.
64. Halley NJ, Areu MT, Achkar JP, Bernstein CN, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011; 106(Suppl 1): 1–24.
65. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroide therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 590–599.
66. Khan KJ, Dubinsky MC, Ford AC, et al. Efficacy of immunosupresive therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 630–642.
67. Ford AC, Khan KJ, Sandborn WJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 644–659.
68. Beaugerie L, Brousse N, Bouvier AM, et al. Lymfoproliferative disorders in patients receiving thiopurines for inflammatory boel disease: a prospective observational cohort study. Lancet 2009; 374: 1617–1625.
69. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Group Investigatiators. N Engl J Med 2000; 342: 1627–1632.
70. D’Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn‘s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106(2): 199–212.
71. Seow CH, Newman A, Irvin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor for clinical outcome of infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49–54.
72. Guidi L, Pugliese D, Armuzzi A. Update on the management of inflammatory bowel disease: specific role of adalimumab. Clin Experimental Gastroeterol 2011; 4: 163–172.
73. Fiorino G, Szabė H, Fries W, Malesci A, Peyrin-Biroulet L, Danese S. Adalimumab in Crohn’s disease: tips and tricks after 5 years of clinical experience. Curr Med Chemistry 2011; 18(8): 1–9.
74. Pracovní skupina pro idiopatické střevní záněty ČGS. Doporučení pro podávání biologické terapie u idiopatických střevních zánětů. Čes a Slov Gastroent a Hepatol 2008; 62(5): 285–291.
75. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362: 1383–1395.
76. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2008; (1): CD006893.
77. Feagan BG, Léman M, Befrits R, et al. Recommendations for the treatment of Crohn’s disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm Bowel Dis 2012; 18(1): 152–160.
78. Munkholm P. 5-aminosalicylic acid and colorectal cancer prevention in inflammatory bowel disease. Eur Gastroenterol. Hepatol Review 2011; 160–165.
79. Bergman R, Parkes M. Systematic review the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 23: 841–855.
80. Baden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a metaanalysis. Gut 2001; 48: 526–535.
81. Sutherland L, Macdonald JF. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; CD000544.
82. Turunen UM, Farkilla MA, Hakala K, t al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective double-blind, placebo controlled study. Gastroenterology 1998; 115: 1072–1078.
83. Verma S, Kirkwood B, Brown S, Giaffer MH. Oral nutritional supplementation is effective in the maintenance of remission in Crohn’s disease. Dig Liver Dis 2000; 32(9): 769–774.
84. Akobeng AK, Thomas AG. Enteral nutrition for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2007; (3): CD005984.
85. Leung Y, Heyman MB, Mahadevan U. Transitioning adolescent inflammatory bowel disease patient: guidelines for the adult and pediatric gastroenterologist. Inflamm Bowel Dis 2011; 17(10): 2169–2173.
86. Kim PS, Zlatanic J, Korelitz BI, et al. Optimum duration of treatment with 6-mercaptopurine for Crohn’s disease. A J Gastroenterol 1999; 94: 3254–3257.
87. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease. Gut 2002; 50: 485–489.
88. Léman M, Mary JY, Colombel J-F, et al. A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128: 1812–1818.
89. Bradford K, Shih DQ. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol 2011; 17(37): 4166–4173.
90. Trenton X, Bouhnik Y, Mary JY, et al. Azathioprine withdrawal in patients with Crohn’s disease maintained on prolonged remission under treatment is associated with a high risk of relapse. Gastroenterology 2004; 126(Suppl 2): A113.
91. Karaca C. Methotrexate dose in current ECCO consensus on Crohn’s disease. J Crohns Colitis 2010; 4(4): 483.
92. Kamm MA, Ng SC, De Cruz P, Allen P, Hanauer SB. Practical application of anti-TNF therapy for luminal Crohn’s disease. Inflamm Bowel Dis 2011; 17(11): 2366–2391.
93. Allez M, Modigliani R. Clinical features of inflammatory bowel disease. Curr Opin Gastroenterol 2000; 16(4): 329–336.
94. Ahmed T, Rieder F, Fiocchi C, Achkar JP. Pathogenesis of postoperative recurrence in Crohn’s disease. Gut 2011; 60 (4): 553–562.
95. Cho SM, Cho SW, Regueiro M. Postoperative management of Crohn’s disease. in: challenges in inflammatory bowel disease. Med Clin N Amer 2010; 94(1): 179–188.
96. McCartney S. Inflammatory bowel disease in transition: challenges and solutions in adolescence care. Frontline Gastroenterology 2011; 2: 237–241.
97. Lindberg E, Jarnerot G, Huidfeldt B. Smoking in Crohn’s disease: effects on localisation and clinical course. Gut 1992; 33: 779–782.
98. Oschenkühn T, D’Haens G. Current misunderstanding in the management of ulcerative colitis. Gut 2011; 60: 1294–1299.
99. Williams RG, Wong WD, Rothenberg DA, Goldberg SM. Recurrence of Crohn’s disease after resection. Brit J Surg 1991; 78(1): 10–19.
100. Papi C, Luchetti R, Gili L, Montani S, Koch M, Capurso L. Budesonide in the treatment of Crohn’s disease: a metaanalysis. Aliment Pharmacol Ther 2000; 14: 1419–1428.
101. Hellers G, Cortot A, Jewell D, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn’s disease. Gastroenterology 1999; 116: 294–300.
102. Rutgeerts P. Review article: recurrence of Crohn’s disease after surgery – the need for treatment of new lesions. Aliment Pharmacol Ther 2006; 24(Suppl 3): 29–32.
103. Colombel JF, Rutgeerts P, Malchow H, et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn’s disease. Gut 2001; 49: 42–46.
104. Marteau P, Lemann M, Seksip P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease. Gut 2006; 55: 842–847.
105. Chermesh I, Tamir A, Reshef R, et al. Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn’s disease. Dig Dis Sci 2007; 52: 385–389.
106. Regueiro M. Management and prevention of postoperative Crohn’s disease. Inflamm Bowel Dis 2009; 15: 1583–1590.
107. Rampton DS. Crohn’s disease recurrence can be prevented after ileal resection. Gut 2002; 51: 153–154.
108. Seksik P, Dray X, Sokol H, Marteau P. Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease? Mol Nutr Food Res 2008; 52(8): 906–901.
109. Pardi DS, D’Haens G, Shen B, Campbell S, Gionchetti P. Clinical guidelines for the management of pouchitis. Inflamm Bowel Dis 2000; 15: 1424–1431.
110. Wu H, Shen B. Pouchitis and pouch dysfunction. Gastroenterol Clin North Am 2009; 38: 651–668.
111. Ewe K, Bottger T, Buhr HJ, Ecker KW, Otto HF. Low dose budesonide treatment for prevention postoperative recurrence of Crohn’s disease: a multicentre randomized placebo--controlled trial. German Budesonide Study Group. Eur J Gastroenterol Hepatol 1999; 11: 277–282.
112. D’Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn’s disease. Gastroenterology 1997; 112: 475–481.
113. D’Haens, G, Noman M, van Assche G, et al. Severe postoperative recurrence of Crohn’s disease is significantly reduced with combination therapy metronidazole + azathioprine. J Crohn Colitis (Suppl) 2007; 1: 4.
114. Papay P, Reinisch W, Miehsler W, et al. Maintenance therapy with azathioprine/6-mercaptopurine in Crohn’s disease reduces the risk of re-operation particulary in smokers. J Crohn Colitis (Suppl) 2008; 2: 3.
115. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–1549.
116. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007; 56: 1232–1239.
117. Saag GS, Ten GG, Patkar NM, et al. Americal college of rheumatology 2008 recommendations for the use of nonbiologic and biologic disease modifying antirheumatic drugs in rheumatoid arthritis. Arthritis & Rheumatism 2008; 59(6): 762–784.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Czech paediatric cardiac surgery – history and presence
- Addition of statins into the public water supply? Risks of side effects and low cholesterol levels
- Long-term therapy of idiopathic inflammatory bowel disease
- Physician and freedom of conscience